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Macrophages play an important role in regulating the tumor microenvironment (TME).
Here we show that classical (M1) macrophage polarization reduced expression of
LSD1, nuclear REST corepressor 1 (CoREST), and the zinc finger protein SNAIL.
The LSD1 inhibitor phenelzine targeted both the flavin adenine dinucleotide (FAD) and
CoREST binding domains of LSD1, unlike the LSD1 inhibitor GSK2879552, which only
targeted the FAD domain. Phenelzine treatment reduced nuclear demethylase activity
and increased transcription and expression of M1-like signatures both in vitro and in
a murine triple-negative breast cancer model. Overall, the LSD1 inhibitors phenelzine
and GSK2879552 are useful tools for dissecting the contribution of LSD1 demethylase
activity and the nuclear LSD1-CoREST complex to switching macrophage polarization
programs. These findings suggest that inhibitors must have dual FAD and CoREST
targeting abilities to successfully initiate or prime macrophages toward an anti-tumor
M1-like phenotype in triple-negative breast cancer.
Keywords: macrophage polarization, LSD1, CoREST, breast cancer, epigenetics, tumor microenvironment, tumor
associated macrophages
INTRODUCTION
Breast cancer is the most common female cancer worldwide (1). The triple-negative subtype of
breast cancer (TNBC) accounts for 15–20% of cases (2, 3) and is characterized by an absence of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2)
expression (3–5). TNBC patients have a worse prognosis than patients with other breast cancer
subtypes, not least because they do not have the targets and so do not respond to hormonal or
HER2-targeting therapies. Various novel treatments have been trialed in patients with TNBC, but
standard chemotherapy regimens remain the standard of care (5–7).
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TNBCs have a particularly high immune cell infiltrate
compared to other breast cancer subtypes, but these immune
cells are often functionally impaired (8, 9). The tumor
microenvironment (TME) of any cancer contains a complex
mixture of immune cells with both pro- and anti-tumor
properties. Tumor-associated macrophages (TAMs) are a major
immune cell subset in the TME, where they exist along a
phenotypic spectrum from classically (M1) to alternatively
(M2) activated (10, 11). Lipopolysaccharide (LPS) and IFN-γ-
induced M1 macrophages secrete pro-inflammatory cytokines
and reactive oxygen/nitrogen species that contribute to tumor
cell cytotoxicity. Conversely, IL-4- and IL-13-induced M2
macrophages produce anti-inflammatory cytokines that can
suppress other immune cells in the TME and promote tumor
progression (12–14).
Epigenetic programming plays a significant role in regulating
macrophage polarization and can be manipulated using various
inhibitors (15). Numerous epigenetic enzymes control DNA
methylation, histone methylation, and histone acetylation [see
reviews in (16–18)]. Lysine-specific demethylase 1 (LSD1)
is a H3K4 and H3K9 demethylase essential for myeloid
cell differentiation (19), reactivating key immune checkpoint
regulators, producing cytotoxic T cell chemokines (20), and
preventing IL6 silencing in LPS-tolerant macrophages (21). We
previously showed that immune-incompetent mice treated with
the LSD1 inhibitor phenelzine had a higher proportion of M1-
like macrophages in the TME of xenografts (22). We also showed
that LSD1 is critical for reprogramming cancer stem cell (CSC)-
inducible gene signatures and directly regulates distinct CSC
genes implicated in breast cancer metastasis by tethering to their
promoter regions (22).
Here we show that M1 (IFN-γ + LPS) or M2 (IL-4)
macrophages differentially express LSD1 and nuclear serine
111 phosphorylated LSD1 (LSD1-s111p). LSD1 and LSD1-s111p
downregulation in the M1 (IFN-γ + LPS) phenotype correlates
with decreased nuclear activity and increased expression of
histone H3 lysine 4 dimethylation (H3K4me2) and histone
H3 lysine 9 dimethylation (H3K9me2) marks and decreased
interactions with nuclear REST corepressor 1 (CoREST) and zinc
finger protein SNAI1 (SNAIL) complexes. Phenelzine treatment
mimics the phenotype of these M1 (IFN-γ + LPS) polarized
cells by disrupting the LSD1-CoREST complex unlike the
catalytic inhibitor GSK2879552. Thus, showing the importance
of targeting the LSD1-CoREST complex to epigenetically prime
macrophages toward an M1-like phenotype. In vivo, LSD1
inhibition by phenelzine primes TAMs to express M1-like
gene that displayed both common and unique pathways to
the chemotherapeutic protein-bound paclitaxel (Abraxane).
Phenelzine treatment also led to a higher proportion of
macrophages expressing M1 like protein (iNOS, CD86 and PD-
L1) in formalin-fixed paraffin embedded (FFPE) tissue sections
of tumors from a murine model of triple negative breast cancer
(TNBC). Collectively, our data show for the first time that
LSD1 inhibitors that target the LSD1 FAD and disrupt the
LSD1-CoREST complex leading to a destabilization of LSD1 can
epigenetically prime macrophages toward a M1-like phenotype
in the TME, and future immunomodulatory drug development
must take LSD1 FAD and LSD-CoREST complex into account to
improve efficacy.
MATERIALS AND METHODS
Cell Culture
RAW264.7 cells (ATCC TIB-71) were cultured in high-glucose
DMEM with 2mM L-glutamine, 1 x penicillin-streptomycin-
neomycin (PSN) (Gibco, Thermo Fisher Scientific, Waltham,
MA), and 10% heat-inactivated fetal calf serum (FCS). 4T1
cells (ATCC CRL-2539) were cultured in DMEM with 2mM
L-glutamine, PSN, and 10% heat-inactivated FBS. Transfection
reactions were performed with 10 nM mouse LSD1 siRNA (sc-
60971) and mock siRNA (sc-37007) (Santa Cruz Biotechnology
Inc., Dallas, TX) using Lipofectamine 2,000 (Invitrogen,
Carlsbad, CA).
In vitro Macrophage Polarization
RAW264.7 cells were seeded into 6- or 12-well plates 24 h before
polarizing macrophages. M1 (IFN-γ + LPS) classical activation
was induced by adding 100 ng/ml lipopolysaccharide (LPS) and
20 ng/ml IFN-γ, andM2 (IL-4) alternative activation was induced
by adding 20 ng/ml IL-4 for 24 h. Phenelzine and GSK2879552
(GSK) were added at 500µM for 24 h.
RNA Extraction and Quantitative
Real-Time PCR
Total RNA was extracted from RAW264.7 cells using the
RNeasy Micro kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocols. RNA was measured using the
Nanodrop spectrophotometer (Thermo Fisher Scientific)
and reverse transcribed into cDNA using the SuperScript
VILO cDNA synthesis kit using the manufacturer’s protocols.
TaqMan quantitative real-time PCR was performed with the
following mouse TaqMan probes: Nos2 (Mm00440502_m1),
Gpr18 (Mm02620895_s1), IL6 (Mm00446190_m1),
Fpr2 (Mm00484464_s1), IL12b (Mm00434174_m1), ILb
(Mm00434228_m1), CCR7 (Mm01301785_m1), Myc
(Mm00487804_m1), Egr2 (Mm00456650_m1), Arg1
(Mm00475988_m1), Mrc1 (Mm00485148_m1), Mgl2
(Mm00460844_m1), Pdcd1 (Mm01285676_m1), CD274
(Mm03048248_m1), Pdcd1lg2 (Mm00451734_m1), KDM1A
(Mm01181029_m1), and Gapdh (Mm99999915_g1). DNA from
formaldehyde-assisted isolation of regulatory elements (FAIRE)
was quantified by SYBR real-time PCR with the primer set
listed in Supplementary Table 1. qPCR data were normalized to
Gapdh loading control.
Formaldehyde-Assisted Isolation of
Regulatory Elements (FAIRE)
FAIRE samples were prepared as outlined in Simon et al. (23).
Briefly, cells were cross-linked with 1% formaldehyde and lysed.
The cell lysates were sonicated to yield an average DNA fragment
distribution of ∼200–500 bp. A 50µl aliquot of fragmented
DNA (total input control DNA) was reverse cross-linked at
65◦C followed by phenol-chloroform extraction. The remaining
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sonicated DNA (FAIRE DNA) was directly isolated by phenol-
chloroform extraction and purified using the Zymo-SpinTM I kit
(Zymo Research, Irvine, CA).
Animal Studies
Five-week-old female BALB/c mice were obtained from the
Animal Resources Center (ARC), Perth, and allowed to
acclimatize for 1 week in the containment suites at The John
Curtin School of Medical Research (JCSMR). All experimental
procedures were performed in accordance with the guidelines
and regulations approved by the Australian National University
Animal Experimentation Ethics Committee (ANU AEEC).
Mice were shaved at the site of inoculation the day before
subcutaneous injection with 2 × 105 4T1 cells in 50 µl
PBS into the right mammary gland. Treatment was started
at day 12 post inoculation, when tumors reach approximately
50 mm3. Tumors were measured using external calipers and
volumes calculated using a modified ellipsoidal formula ½
(a/b2), where a = longest diameter and b = shortest diameter.
Mice were treated with Abraxane (30 mg/kg) and PD1 (10
mg/kg) every 5 days (twice) and phenelzine (40 mg/kg) daily.
All treatments were given intraperitoneally in PBS. Tumors
were collected on day 27 post-inoculation of 4T1 cells for
flow cytometry, macrophage enrichment for NanoString, and
immunofluorescence microscopy.
Tumor Dissociation Protocol
4T1 tumors were harvested in cold DMEM supplemented with
2.5% FCS before being finely cut using surgical scalpels and
enzymatically dissociated using collagenase type 4 (Worthington
Biochemical Corp. Lakewood, NJ) at a concentration of 1mg
collagenase / 1 g of tumor at 37◦C for 1 h. Dissociated cells were
then passed through a 0.2µM filter before downstream assays.
Flow Cytometry
Single cell suspensions were prepared as in the tumor dissociation
protocol. Non-specific labeling was blocked using anti-CD16/32
(Fc block; BD Biosciences, Franklin Lakes, NJ) before specific
labeling. BD Horizon fixable viability stain 780 was used to
distinguish live and dead cells. Tumor cells were stained with
antibodies targeting F4/80 PE, CD206 APC, and Ly6C Brilliant
Violet 421 (all from BioLegend, San Diego, CA). Sample
acquisition was performed with the BD LSR II cytometer and
results analyzed with FlowJo software.
Macrophage Enrichment and NanoString
nCounter Protocol
Single cell suspensions were magnetically labeled with anti-F4/80
microbeads UltraPure (Miltenyi Biotec, Bergisch Gladbach,
Germany) in MACS running buffer. Macrophages were
then positively isolated using the autoMACS Pro Separator
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s protocols. Enriched cells were then snap
frozen and RNA isolated using the RNeasy Mini kit (Qiagen).
Samples were analyzed using the NanoString platform according
to the manufacturer’s procedures. Briefly, 100 ng of RNA was
hybridized with the mouse myeloid innate immunity panel
codeset for 18 h at 65◦C. Samples were then loaded onto the
chip via the nCounter prep station and data acquired using the
nCounter Digital Analyzer. Data analysis was performed using
nSolver Analysis Software. The Benjamini-Yekutelli method was
used to calculate the false discovery rate (FDR) (24).
Immunofluorescence
Cells were cultured for 24 h on sterilized coverslips and then
for a further 24 h after treatment with either complete medium,
100 ng/mL LPS and 20 ng/mL IFN-γ, 20 ng/mL IL-4, 500µM
phenelzine, or 500µM GSK to form the treatment groups:
control, M1 (IFN-γ + LPS), M2 (IL-4), phenelzine, and
GSK, respectively.
After culturing, cells were fixed with 3.7% paraformaldehyde
and permeabilized using 2% Triton X-100 solution. Cells were
then blocked using 1% bovine serum albumin (BSA) and probed
with rabbit-LSD1p (ABE1462, EMD Millipore, Burlington,
MA), mouse-H3K9me2 (ab1220, Abcam, Cambridge, UK),
goat-H3K4me2 (ab11946, Abcam), mouse-CD38 (102716,
BioLegend), and goat-SNAIL1 (sc-10433, Santa Cruz
Biotechnology) followed by visualization with corresponding
secondary antibodies (all Thermo Fisher Scientific): anti-
rabbit (A21206 and A10042), anti-mouse (A10037), and
anti-goat (A21082 and A11055) conjugated to either Alexa
Fluor 488, or 568, or 633. Coverslips were mounted onto
glass microscope slides using SlowFadeTM Diamond Antifade
Mountant with DAPI.
Formalin-fixed, paraffin-embeddedmelanoma primary tumor
biopsies were processed in the BondRX for OPAL staining
(Perkin-Elmer, Waltham, MA) using the instrument protocol:
ER1 for 20min at 100◦C with Epitope Retrieval Solution
(pH6 Citrate-based retrieval solution) followed by probing
with primary antibodies to F4/80 (ab100790, Abcam), iNOS
(ab115819, Abcam), CD86 (ab213044, Abcam) and PD-L1
(ab2386097, Abcam) (for the M1 panel) or F4/80, EGR2
(ab90518, Abcam), CD206 (ab64693, Abcam) and PD-L2
(PAB12986, Abnova) (for theM2 panel). Primary antibodies were
visualized with an Opal Kit 520, 570, 650, and 690. Coverslips
were mounted on glass microscope slides with ProLong Clear
Antifade reagent (Life Technologies, Carlsbad, CA). Opal kits
used: 7-color automation kit (NEL801001KT) and the 4-color
automation kit (NEL820001KT).
Slides were observed under a Leica DMi8 inverted microscope
running Leica Application Suite X software. Multiple images
were taken at various positions on the slide using a 100x oil
immersion lens. Images were analyzed using ImageJ software,
with the fluorescence intensity measured from a minimum of 20
cells and an average total fluorescence of either the nucleus or
cytoplasm reported. Background fluorescence was measured and
subtracted from all results.
For high-throughput microscopy, protein targets were
localized by confocal laser scanning microscopy. Single 0.5µm
sections were obtained using an Olympus-ASI automated
microscope with 100x oil immersion lens running ASI software.
The final image was obtained by employing a high throughput
automated stage with ASI spectral capture software. Digital
images were analyzed using automated ASI software (Applied
Frontiers in Immunology | www.frontiersin.org 3 June 2019 | Volume 10 | Article 1351
Tan et al. LSD1 Role in Macrophage Polarization
Spectral Imaging, Carlsbad, CA) to automatically determine the
distribution and intensities with automatic thresholding and
background correction of either the average nuclear fluorescent
intensity (NFI) and average or whole cell total fluorescent
intensity (TFI). The plot-profile feature of ImageJ was used to
plot the fluorescence signal intensity along a single line spanning
the nucleus (n = 5 lines per nucleus, 5 individual cells) using
the average fluorescent signal intensity for the indicated pair of
antibodies plotted for each point on the line with SE. Signal was
plotted to compare how the signals for each antibody varied
compared to the opposite antibody. For each plot-profile, the
PCC was determined in ImageJ. PCC indicates the strength of
relationship between the two fluorochrome signals for at least
20 individual cells ± SE. Colors from representative images
correspond to plot-profiles.
LSD1 Activity Assay
Nuclear extracts were prepared as previously described from
cells, and 5 µg of protein/well in triplicate was used to measure
LSD1 demethylase activity using the Abnova LSD1 Demethylase
Activity/Inhibition assay kit (Abnova, Taipei City, Taiwan)
according to the manufacturer’s protocol.
X-Ray Crystallography
Recombinant human LSD1 encoding residues 173-830 was
expressed in E. coli BL21(DE3)pLysS using auto-induction
medium (Studier, 2005) from the pMSCG21 expression vector.
Cells were grown at 25◦C, harvested by centrifugation, and
resuspended in His buffer A (50mM phosphate buffer, 300M
NaCl, and 20mM imidazole). Resuspended cells were lysed by
two repetitive freeze-thaw cycles and the cell lysate clarified by
centrifugation. The soluble cell lysate was filtered using a 0.45µm
low protein binding filter and injected onto a 5mL Ni-Sepharose
HisTrap HP column equilibrated with His buffer A. Following
sample injection, the column was washed with 15 column
volumes of His buffer A, then eluted with His buffer A containing
500mM imidazole. The purified protein was purified further by
size exclusion chromatography and applied to a pre-equilibrated
Superdex 200 26/60 size exclusion column. The protein was
concentrated to 17 mg/ml using an Amicon ultracentrifugal
device with a 10 kDa molecular weight cut off, aliquoted and
stored at −80◦C. The LSD1 protein was screened for conditions
that induce crystals, with diffraction quality crystals obtained in
2–15% PEG 3350, ammonium citrate pH 6.5 and pH 7.0. A 10-
molar excess of phenelzine sulfate or GSK2879552 was added to
the LSD1 prior to crystallization, with a notable change in color
from yellow to pale yellow/clear.
All X-ray diffraction data were collected on the MX1
crystallography beamline at the Australian Synchrotron. Images
were indexed and integrated in iMosfilm (25), and data merged
and scaled in Aimless (26). The number of molecules within the
asymmetric unit was estimated based on theMatthews coefficient
(VM) and the predicted molecular weight of the protein (27, 28).
Model building and refinement was performed using COOT (29)
and REFMAC (30).
Bioinformatic Analysis
Promoter and enhancer analysis was performed on significant
genes (p < 0.05, False Discovery Rate (FDR) < 0.15) up or
down-regulated by phenelzine from the NanoString nCounter
assay. Benjamini-Yekutieli false discovery rate method was
used to calculate the FDR (24). Enhancer regions are from
Supplementary Table 1 in Ostuni et al. (31). Raw data was
downloaded from GEO, GSE38377, GSE91009 and GSE78873
and adapter trimmed and mapped to mm9 using Trimmomatic
(32) and Bowtie2 (33) in Galaxy. CpG and GC, and histone levels
were calculated with HOMER (34). Counts for promoters [were
1 kb ± around the transcription starts site (TSS)], and enhancer
regions (using the given range). Accessibility and histone levels
for stimulated and non-stimulated cells were equalized to the
mean promoter values for all RefSeq genes. Bedtools (35) was
used to detect which enhancers were within 10 kb of the gene TSS.
Welch two sample t-test and boxplots were performed in R.
Statistics
All statistical comparisons between sample groups were
calculated using the two-tailed non-parametric Mann-Whitney
test (GraphPad Prism, San Diego, CA) unless otherwise
indicated. Where applicable, statistical significance is denoted by
∗P ≤ 0.05, ∗∗P ≤ 0.005, ∗∗∗P ≤ 0.0005 and ∗∗∗∗P ≤ 0.0001. Data
are expressed as mean± SE.
RESULTS
Phenelzine and GSK2879552 Modify the
LSD1 Flavin Adenine Dinucleotide (FAD)
Cofactor
We previously showed that LSD1 modulates epithelial to
mesenchymal transition in CSCs and that LSD1 inhibition
promotes an M1-type response in an immune-deficient mouse
cancer xenograft model (22). Here we aimed to further
characterize the effect of LSD1 inhibition on macrophage
polarization utilizing two different LSD1 inhibitors, phenelzine,
and GSK2879552 (GSK).
Phenelzine and GSK are monoamine oxidases (MAOs) and
effective LSD1 inhibitors (36, 37), probably via modification of
the flavin adenine dinucleotide (FAD) cofactor (38, 39). We
first confirmed whether the inhibitors act via a FAD-dependent
mechanism by crystallizing LSD1 in the presence and absence of
phenelzine andGSK. The gross crystal morphology wasmarkedly
different: yellow in the absence of inhibitor and translucent
in the presence of phenelzine or GSK (Figure 1A). However,
the crystals diffracted to similar resolution and belonged to the
same space group (Supplementary Table 2), each containing one
LSD1 molecule in the asymmetric unit.
In the absence of inhibitor, there was clear density
corresponding to FAD (Figure 1A). In the presence of
phenelzine, there was clear positive density at the central
nitrogen of the flavin moiety on FAD, consistent with a
previously determined structure of human MAO-B in the
presence of phenelzine (PDB 2VRM). This is also consistent
with the observed color change, since the flavin moiety confers
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FIGURE 1 | Phenelzine targets the FAD domain of LSD1 and potentially disrupts the LSD1/CoREST axis resulting in destabilization of LSD1 and its nuclear activity. (A)
LSD1 protein crystals (top panel) grown in the absence (left) and presence of phenelzine (middle) and GSK2879552 (right). In the absence of inhibitors, strong density
(bottom panels) was observed consistent with the FAD cofactor (shown as sticks colored with carbons black, nitrogen blue, oxygen red, and phosphate orange). The
map is a simulated annealed omit map for FAD contoured at 2.5 sigma. LSD1 is colored gray and shown in cartoon mode. The FAD modifications by phenelzine
(middle) and GSK (right) are supported by strong density, with corresponding maps and colors as per LSD1:FAD. (B) Structural superposition of LSD1 in the absence
and presence of phenelzine and GSK. The structures solved in this study (left panel), LSD1 alone (pink) (PDB 6NQM), LSD1:GSK (yellow) (PDB 6NQU), and
LSD1:phenelzine (green) (PDB 6NR5) are represented in cartoon mode. These structures are superimposed in the left panel, showing a high degree of structural
homology in the LSD1 catalytic domain for all three structures. LSD1 alone and LSD1:GSK also show high structural conservation in the alpha-helical tails; however,
LSD1:phenelzine has a 5.4 Å displacement in this region. This region is important for CoREST binding, as shown in the middle panel (PDB 2UXX). Superposition of all
structures in the left and middle panels is shown on the right, highlighting that CoREST binding is mediated by the correct position of these domains. All images were
generated in Pymol. (C) The plot-profile feature of ImageJ was used to plot the fluorescence signal intensity along a single line spanning the nucleus (n = 5 lines per
nucleus, 5 individual cells) using the average fluorescent signal intensity for the indicated pair of antibodies plotted for each point on the line with SE. (D) Pearson’s
correlation coefficient (PCC) indicating the colocalization of LSD1/CoREST and CoREST/SNAIL. *p < 0.05, **p< 0.005, ***p < 0.0005, ****p < 0.0001 Mann–Whitney
t-test.
these spectral properties (40). Similarly, LSD1 protein crystals
grown in the presence of GSK exhibited clear additional positive
density at the flavin moiety, consistent with a previous crystal
structure of LSD1 bound to a GSK analog (PDB 2UXX) (41).
Both inhibitors appear to act via similar mechanisms and modify
the FAD cofactor at the flavin moiety.
The inhibitor-bound structures were superimposed and
compared with the native LSD1 structure to examine whether
these inhibitors resulted in any other observable structural
changes. Phenelzine resulted in a small 5.4Å shift in the long
alpha-helical tails of LSD1 (residues 415–514) (PDB 6NR5) that
was not present in LSD1 (PDB 6NQM) or LSD1:GSK2879552
crystals (PDB 6NQU). This region mediates CoREST binding,
making it possible that phenelzine-induced structural changes
in this region may also affect LSD1 activity outside the catalytic
region (Figure 1B).
LSD1 Inhibitors Differentially Target or
Disrupt the LSD1/CoREST Complex in
Macrophages
Given that phenelzine-induced structural changes in the CoREST
region (Figure 1B) may affect LSD1 activity outside the
catalytic region, we examined the impact of phenelzine on
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the LSD1/CoREST complex and its impact on macrophage
polarization by comparing unpolarized, M1 or M2 polarized,
and phenelzine- or GSK-treated RAW264.7 cells in vitro by
high-resolution fluorescent confocal microscopy (Figure 1C).
Phenelzine treatment or M1 polarization with IFN-γ and
LPS significantly reduced the number and nuclear expression
of CoREST, LSD1, and SNAIL in RAW264.7 macrophages
(Figure 1C). The nuclear to cytoplasmic ratio of LSD1 (Fn/c)
was almost equal, suggesting downregulation of LSD1 in both the
cytoplasmic and nuclear compartments on phenelzine treatment
(Supplementary Figure 1). Conversely, treatment with either
GSK or M2 polarization with IL-4 had the opposite effect, with
enhanced cell number and expression intensity of CoREST and
LSD1 and an overall increase in expression of CoREST, LSD1,
and SNAIL in both the cytoplasmic and nuclear compartments.
However, in this case, the Fn/c of LSD1 was clearly nuclear biased
in the control group and increased further by M2 polarization or
GSK treatment, perhaps by stabilizing LSD1 in the nucleus and
enhancing expression (Figure 1C).
Phenelzine treatment abrogated co-localization of LSD1 and
CoREST or SNAIL and CoREST as indicated by a strong negative
PCC score in the phenelzine-treated samples (Figure 1D). GSK
induced the opposite, with LSD1 and CoREST or SNAIL
and CoREST strongly co-localizing with a positive PCC score
(Figure 1D).
Overall, these data suggest that M1 (IFN-γ + LPS)
polarization destabilizes and globally reduces LSD1, SNAIL, and
CoREST expression, the overall cell population expressing these
markers, and CoREST/LSD1 and CoREST/SNAIL complexes.
Cells treated with phenelzine mimics this phenotype, impacting
on both the FAD and CoREST domains of LSD1. Conversely,
GSK or M2 (IL-4) polarization stabilizes and induces nuclear
LSD1 and CoREST expression by enhancing their spatial co-
localization. This suggests that overall that phenelzine inhibition
aligns with M1 (IFN-γ + LPS)—macrophage polarization in
the context of inhibiting both the catalytic FAD and nuclear
CoREST domain of LSD1 Nuclear LSD1 activity can determine
the macrophage phenotype.
To address the impact of LSD1 on macrophage polarization,
we employed high-throughput, ASI Digital Pathology Platform
which allows both the quantification of immuno-fluorescent
intensity and population distribution of stained cells using
proprietary algorithms developed in partnership with
ASI:Metagene using automatic autofluorescence correction
with automatic signal intensity and cell detection to detect up
to 6 colors plus DAPI. This system was employed to analyze
both the expression and population distribution of the M1
marker CD38 and M2 marker EGR2 in RAW264.7 mouse
macrophages treated with phenelzine, GSK, or cytokine-induced
M1 (IFN-γ + LPS) or M2 (IL-4) phenotypes. Treatment with
M1 (IFN-γ + LPS) or phenelzine reduced expression of EGR2
(an M2 marker) and the overall percentage of cells positive
for EGR2 in F4/80+ RAW264.7 cells (Figure 2A), whereas
induction with M2 (IL-4) or treatment with GSK induced
expression of EGR2 and increased the percentage of EGR2+ cells
(Figure 2A). Conversely, phenelzine treatment or M1 (IFN-γ +
LPS) induction increased expression of the M1 marker CD38
and increased the proportion of CD38+ cells (Figure 2A), and
M2 (IL-4) polarization and GSK treatment significantly reduced
both expression of CD38 and the percentage of CD38+ cells.
Thus, different LSD1 inhibitors have different and opposing
effects on macrophage polarization.
We previously reported the importance of nuclear LSD1
phosphorylation at serine 111 (LSD1-s111p) in both CSCs
and macrophages within the TME (22). We also showed that
LSD1 inhibition significantly reduces LSD1-s111p and the
transcription factor SNAIL expression in circulating tumor
cells (CTCs) (22). We therefore sought to determine the
impact of these LSD1 inhibitors on LSD1 activity and how
M1 (IFN-γ + LPS) or M2 (IL-4) macrophage polarization
affects the nuclear distribution of LSD1-s111p using high-
resolution immunofluorescent microscopy for LSD1-s111p,
histones modifications H3K9Me2 and H3K4me2, and SNAIL
in RAW264.7 macrophage nuclei. H3K4 and H3K9 are direct
LSD1 targets, and overexpression of the transcription factor
SNAIL is associated with M2-like macrophage polarization
(19, 42). Phenelzine treatment significantly reduced nuclear
LSD1-s111p levels to like those seen in M1-polarized
macrophages and enhanced levels of H3K9me2 and H3K4me2
(Supplementary Figure 1). Conversely, there was increased
LSD1-s111p and decreased H3K9me2 and H3k4me2 levels in
M2 andGSK-treated cells (Supplementary Figure 1). Phenelzine
also reduced LSD1 nuclear enzymatic activity. Polarizing cells
toward an M1 phenotype using IFN-γ and LPS also reduced
nuclear LSD1 activity compared to controls (Figure 2B).
However, treatment of cells with IL-4 (M2) and GSK did not
inhibit the nuclear activity of LSD1 (Figure 2B). Interestingly,
we also observed similar morphological changes between IFN-γ
+ LPS and phenelzine treatment after 7 days (phenelzine and
media changed every 2 days) (Figure 2C).
Therefore, phenelzine can target nuclear LSD1 activity and
have a role in initiating/priming macrophage polarization that is
likely a pre-requisite for initiating phagocytosis.
Phenelzine Treatment Can Reprogram
Macrophages to Exhibit M1-Like Gene
Signatures With PD1, PD-L1, and PD-L2
Checkpoint Expression
Given the similarities between M1 (IFN-γ + LPS)-polarized
macrophages and macrophages treated with phenelzine, we
next determined whether LSD1 inhibition with phenelzine and
GSK mimic polarized macrophage gene signatures. The gene
expression of phenelzine-treated cells was similar to the M1
phenotype (Nos2, Gpr18, IL6, Fpr2, IL12b, ILl1b, and Ccr7) (12)
induced by IFN-γ and LPS (Figure 3A). This corresponded to
increased accessibility at the promoter (Figure 3C) and enhancer
(Figure 3D) regions of those M1-like genes in the M1 (IFN-γ +
LPS) or phenelzine treated RAW264.7 cells. In addition, genes
associated with the M2 phenotype (Myc, Egr2, Arg1, Mrc1, and
Mgl2) were expressed at much lower levels compared to cells
polarized toward anM2 phenotype using IL-4 (Figure 3B). GSK-
induced gene signatures, on the other hand, did not show a
similar correlation with M1-polarized cells (Figures 3A,B).
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FIGURE 2 | Phenelzine or M1 polarization upregulates M1 protein CD38 and targets the nuclear activity of LSD1. RAW264.7 cells were treated with LPS + IFN-γ,
IL-4, or 500µM phenelzine or GSK for 24 h. Protein targets (A) EGR2 and CD38 in F4/80+ cells were localized by confocal laser scanning microscopy. Single 0.5µm
optical sections were obtained using an Olympus-ASI automated microscope with 100x oil immersion lens running ASI software. The final image was obtained by
employing a high-throughput automated stage with ASI spectral capture software. Digital images were analyzed using automated ASI software to determine the
distribution and intensities automatically with automatic thresholding and background correction. Graphs represent either a dot plot of the individual cell intensities or
the average TFI (n = 2,000 cells). (B) LSD1 activity assay on nuclear extracts of RAW264.7 cells either untreated, M1/M2 polarized, or treated with phenelzine, GSK,
or LSD1 inhibitor tranylcypromine. (C) Images of RAW264.7 cells treated with vehicle control, LPS + IFN-γ (M1), and IL-4 (M2) for 24 h. Phenelzine and GSK treated
cells did not show morphology changes in 24 h (data not shown). In comparison, cells were treated with Phenelzine or GSK for 7 days.
In order to confirm these effects were due to LSD1 inhibition,
we knocked-down LSD1 in RAW264.7 cells with siRNAs. This
resulted in a 40% inhibition of LSD1 gene expression (Figure 3E)
and an increase in key M1 markers such as Nos2 and Il-6, a
decrease in M2 markers Egr2 and no change in Mrc1 (CD206)
(Figure 3E).
Therefore, inhibiting the catalytic FAD and nuclear CoREST
domain of LSD1 with phenelzine can upregulate M1-associated
genes and decrease M2-associated genes, while inhibition of
the FAD domain (GSK) alone does not. This indicates an
important role for both the FAD domain of LSD1 and its
stabilization by CoREST in regulating genes associated with
M1 macrophages.
Targeting the PD1-PD-L1 axis is an effective therapeutic
approach in cancer, and macrophages express these checkpoint
molecules (43, 44). Unpolarized and M1 (IFN-γ + LPS)- and
M2 (IL-4)-polarized RAW264.7 cells express different levels of
PD1, PD-L1, and PD-L2, so given the effect of LSD1 inhibition on
macrophage polarization, we also wanted to determine the effect
of LSD1 inhibition on the PD1-PDL1/2 axis.
Pd1 expression was generally lower in all treated cells
compared to controls (Figure 3F), with M1 (IFN-γ +
LPS)-polarized cells expressing the lowest Pd1 (Figure 3F),
Interestingly, we observe high enrichment of Pd-l1
(approximately 450-fold) and Pd-l2 (approximately 3-fold)
in M1 (IFN-γ + LPS) and M2 (IL-4)-polarized cells,
respectively compared to control (Figure 3F). Phenelzine-treated
macrophages displayed similar Pd-l1 and Pd-l2 expression to M1
(IFN-γ + LPS)-polarized cells except for Pd1 (Figure 3F). GSK
treatment, however, mimicked an M2 (IL-4)-type expression
pattern of Pd-l1 but not Pd1 and Pd-l2 (Figure 3F).
These data suggest that macrophage polarization may
contribute to Pd-l1 and Pd-l2 expression at both the gene and
protein level, with M1 (IFN-γ + LPS)-polarized cells expressing
higher Pd-l1 levels and M2 (IL-4)-polarized cells expressing
higher Pd-l2 levels. Phenelzine treatment appears to mimic
this M1(IFN-γ + LPS)-like checkpoint protein expression but
GSK induces greater variability, suggesting that other post-
translational mechanisms may be involved.
Phenelzine Treatment Can Produce More
Favorable Macrophage Signatures in the
TME That Mimic Those Seen With
Protein-Bound Paclitaxel (Abraxane) and
PD1-Based Immunotherapy
We next sought to determine if phenelzine treatment also
reprograms macrophages in the TME of cancers in mice.
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FIGURE 3 | LSD1 can regulate genes associated with macrophage polarization toward an M1 phenotype and checkpoint molecules. RAW264.7 cells were untreated
or treated with LPS + IFN-γ (M1), IL-4 (M2), or 500 µM of phenelzine or GSK for 24 h. Quantitative real-time PCR of genes associated with (A) M1-associated genes
and (B) M2-associated genes were used to compare different treatment groups. Graphs are represented as mRNA levels normalized to GAPDH. Graphs show means
± SE (n = 3). *p < 0.05, **p < 0.005 Mann-Whitney t-test. (C) and (D) shows chromatin accessibility of genes in the promoter (C) and enchancer (D) regions of
associated genes using quantitative real-time PCR using FAIRE samples. (E) 10nM LSD1 siRNA transfected cells and (F) checkpoint molecules and were used to
compare different treatment groups.
Since chemotherapy is the standard of care for breast cancer
patients and given our results on PD1 expression in response
to phenelzine treatment, we also treated syngeneic TNBC
4T1 mice with protein-bound paclitaxel (Abraxane) and PD1
immunotherapy (Figure 4A). Phenelzine, Abraxane and PD1
reduced tumor volumes (Figure 4B) compared to controls,
however, this difference was not significant.
There were no significant differences in total F4/80+
macrophages between treatment groups (Figure 4C). However,
all three treatments induced significantly lower proportions
of inflammatory (F4/80+Ly6C+) and M2-like macrophages
(F4/80+CD206+) (Figure 4C). We next quantified F4/80 and
M1-like markers (iNOS, CD86 and PD-L1) (Figure 4D) or M2-
like markers (EGR2, CD206, and PD-L2) (Figure 4E) in tissue
sections from individual tumors using the high-throughput,
ASI Digital Pathology Platform as described above in section
Phenelzine Treatment Can Reprogram Macrophages to Exhibit
M1-Like Gene Signatures With PD1, PD-L1, and PD-L2
Checkpoint Expression (Figures 4F,G). There was a significant
increase of F4/80 macrophages expressing three M1-like markers
with phenelzine and PD1 treatment alone compared to control
and Abraxane treated mice (Figure 4F). Further, there was
a significant decrease in F4/80 macrophages expressing all
three M2-like markers with phenelzine and PD1 treatment
compared to control and Abraxane treated mice (Figure 4G).
Interestingly, treatment with Abraxane alone decreased the
number of macrophages expressing the M1-like markers and
significantly increased the number of macrophages expressing
M2-like markers (Figures 4F,G).
The macrophages were then analyzed for innate immunity
pathways (770 genes, 19 default pathway annotations) using
the NanoString platform. Phenelzine, Abraxane, and PD1 all
modulated key M1 gene signatures compared to macrophages
from control mice (Figures 5A,B), although PD1-related changes
were non-significant.
Macrophages are professional antigen-presenting cells and
express various co-stimulatory molecules that help with antigen
presentation to T cells via MHC class II (45, 46). Phenelzine
or Abraxane upregulated some MHC II genes, positive
co-stimulatory genes such as Cd80, Cd86, Cd40, and Icos-l,
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FIGURE 4 | Phenelzine treatment polarizes macrophages in the tumor microenvironment toward an M1 phenotype. (A) Treatment regime using the BALB/c 4T1
breast cancer model. (B) Tumor volumes of mice treated with vehicle control, Abraxane, Phenelzine or PD1 (n = 4/5). (C) Flow cytometry for total macrophages,
inflammatory macrophages, and M2-like macrophages in the TME. *p < 0.05, Mann–Whitney t-test (n = 4/5). Representative images of (D) M1 and (E) M2 staining of
FFPE tumor tissues in 4T1 mouse model. (F) Sections of primary 4T1 tumors were fixed and IF microscopy performed probing with M1 focused primary antibodies to
F4/80, iNOS, CD86, and PDL1 with DAPI (green = F4/80 red = iNOS, yellow = CD86, cyan = PDL1, blue = DAPI). The population % of F4/80 cells positive for iNOS,
CD86 and PDL1 was measured using ASI’s mIF system. Representative images for each dataset are shown. Graphs plots represent the % population (n ≥ 500 cells
profiled per a group, n = 4 mice). (G) Section of primary 4T1 tumors were fixed and IF microscopy performed probing with M2 focused primary antibodies to F4/80,
EGR2, CD206, and PDL2 with DAPI (green = F4/80 red = EGR2, yellow = CD206, cyan = PDL2, blue = DAPI). The population % of F4/80 cells positive for EGR2,
CD206, and PDL2 was measured using ASI’s mIF system. Representative images for each dataset are shown. Graphs plots represent the % population (n ≥ 500 cells
profiled per a group, n = 4 mice).
and downregulated negative regulators such as B7-H3 in
macrophages in the TME (Figure 5C). Genes were also
upregulated in a subset of CD169+ macrophages (Figure 5D).
Therefore, phenelzine had a significant impact on the genetic
reprogramming of macrophages toward a more M1-like
phenotype in the TME in mice.
The Macrophage Post-translational
Modification Landscape of Genes
Up-Regulated in Phenelzine
We next determined how phenelzine treatment affected
macrophage gene expressions measured using the NanoString
platform (FDR < 0.15) by overlaying these data with published
epigenomic data.
The 178 genes up-regulated by phenelzine had promoters
(±1 kb TSS) with significantly (p < 0.01) less CpG and
GC content than either the “unchanged” or down-regulated
genes (Figure 6A). The 38 down-regulated gene promoters
had significantly (p < 0.01) more CpG and GC content than
unchanged gene promoters (Figure 6A).
Up-regulated gene promoters had significantly less H3K4me3
(p < 0.05) but not H3K27ac and H3K4me1 than the down-
regulated gene promoters, in resting RAW264.7 cells (Figure 6B)
(47). Importantly the up-regulated gene promoters had less
H3K27me3 than the unchanged genes, suggesting their non-
maximal gene expression is not due to H3K27me3-mediated
repression (Figure 6B).
Further, the up-regulated promoters were less accessible
in both NS and 6 h LPS-stimulated bone marrow derived
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FIGURE 5 | Nanostring counts (log2 fold-change) from RNA isolated from macrophages in the TME for (A) M1 phenotypic signatures and pathways, (B) M1 signaling
molecules and transcription factors, (C) T cell activation gene signatures, and (D) CD169+ macrophage gene signatures. *Indicates Benjamini–Yekutieli false
discovery rate value < 0.05.
macrophages (BMDMs) than the down-regulated genes but were
more accessible than the unchanged genes (Figure 6C) (48).
The up-regulated promoters had significantly higher
H3K4me1, H3K27ac, and H3K4me3 levels than the unchanged
genes in BMDMs (31) and H3K4me1 and H3K27ac levels
significantly increased (1.6-fold and 2.3-fold respectively) after
24 h LPS stimulation (Figure 6D).
Using enhancer regions identified in Ostuni et al. (31), we
determined how many of the up- and down- regulated genes had
enhancers within 10 kb of their TSS. Significantly more of the up-
regulated genes had constitutive or constitutive but not steady
(24 h_CONST) macrophage enhancers than all the entire set of
genes. This is consistent with our chromatin accessibility profiles
in Figures 3C,D.
LSD1 Inhibition and Chemotherapy Target
the Hippo and Wnt Signaling Pathways
Using the NanoString platform, there was higher differential
expression (DE) of NanoString default geneset annotations
between mice treated with Abraxane and phenelzine than to
control (orange) than with PD1 (blue) (Figure 7A, undirected).
The complement activation, interferon and chemokine signaling,
T-cell activation and checkpoint signaling, Th1 activation,
antigen presentation, and TLR signaling pathways had higher DE
(orange) (Figure 7A). Phenelzine showed similar upregulation
of pathways as macrophages from Abraxane-treated mice
(Figure 7A, directed). When the gene signatures were annotated
using KEGG, Abraxane-, and phenelzine-treated groups
upregulated genes associated with the Hippo signaling pathway
and downregulated genes associated with the Wnt signaling
pathway (Figure 7B). Phenelzine treatment also upregulated
genes linked to the Ras signaling pathway, distinct from
Abraxane- and PD1-treated mice (Figure 7B).
We next determined which genes were specific to Abraxane
and phenelzine treatments. The treatments shared 93 gene
signatures, 50 specific to Abraxane and 48 specific to phenelzine
(Figure 7C). The top six NanoString default pathways specific
to Abraxane or phenelzine are shown in Figure 7C. Abraxane
treatment seemed to have a greater impact on genes associated
with antigen presentation that phenelzine (Figures 7C,D), while
phenelzine had a greater effect on genes associated with extra-
cellular matrix remodeling and metabolism (Figures 7C,D).
Although macrophages isolated from the TME of mice treated
with Abraxane and phenelzine showed similar gene expression
changes such as upregulation of M1-like genes and pathways,
these two different treatments also target specific pathways:
antigen presentation in the case of Abraxane-treated mice and
ECM remodeling and metabolism in phenelzine-treated mice.
DISCUSSION
Macrophages form a large component of the TME and may
have anti- or pro-tumorigenic properties, making them a viable
target for cancer immunotherapy. Macrophages are broadly
described as M1 (classical) or M2 (alternative) depending
on their activation, although this is known to represent a
phenotypic spectrum. Here we examined the effects of epigenetic
inhibition of LSD1 on macrophage phenotype in vitro and
in vivo using two different LSD1 inhibitors: GSK, which only
binds to the FAD domain, and phenelzine, which can bind
to the FAD domain and disrupt the LSD1-CoREST complex.
Using these inhibitors, we show for the first time a potential
role for the FAD and LSD1-CoREST complex in mediating
downstream gene signatures to generate an M1-like macrophage
phenotype in vitro and in the TME of mouse triple-negative
breast cancers.
To understand how LSD1 inhibition could affect macrophage
polarization, we utilized two LSD1 inhibitors, GSK and
phenelzine. While both inhibitors bound to the FAD domain,
phenelzine but not GSK induced small structural changes in
the CoREST binding region of LSD1, which has been shown to
be important for LSD1’s activity and stability (49). Phenelzine
disrupted co-expression of nuclear LSD1 and CoREST and
SNAIL and CoREST. Interestingly, when cells were polarized
toward an M1 phenotype using IFN-γ and LPS, there was
similar downregulation of nuclear LSD1 and CoREST, but
this did not occur in M2 polarization with IL-4 or with
GSK treatment. Therefore, phenelzine may play a dual role
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FIGURE 6 | CpG content, GC content, histone marks, and accessibility of genes in the NanoString panel. (A) CpG and GC content, (B,D) histone levels and (C)
accessibility of genes ± 1 kb from transcription start site (TSS) of NanoString genes up-regulated, downregulated (FDR < 0.15), or unchanged (FDR > 0.15) and
genes from refSeq in RAW264.7 cells (47). (C) shows accessibility of Nanostring genes against gene sets from bone marrow derived macrophages (BMDMs) with or
without 6 h of LPS stimulation (48). (E) Levels of up/down regulated NanoString genes that had enhancers within 10 kb of their TSS from BMDMs with or without 24 h
of LPS stimulation (31). A t-test with unequal variance (Welch two sample t-test) was used with *p < 0.05, **p < 0.01 and ***p < 0.001.
by disrupting the LSD1-CoREST complex and potentially its
stability and activity, while GSK can only bind the FAD domain.
The LSD1-CoREST complex also appears to have a role in
repressing the M1 macrophage phenotype, because there was
similar downregulation of LSD1, CoREST, and SNAIL expression
when the cells were polarized toward an M1 phenotype using
IFN-γ and LPS. However, this was not observed when cells
were polarized to an M2 phenotype or treated with GSK, which
only targets the FAD domain. This highlights the importance
of targeting both the FAD and CoREST domains of LSD1
to reprogram macrophages toward an M1-like phenotype for
therapeutic benefit.
The LSD1-CoREST complex has been shown to promote
demethylation of nucleosomal histone 3 lysine 4 (H3K4) (49, 50)
and histone 3 lysine 9 (H3K9) (51). To determine if LSD1
demethylase activity participates in macrophage polarization,
we used immunofluorescence microscopy to show that cells
treated with phenelzine had higher expression of histone
H3K9me2 and H3K4me2, which are direct targets of LSD1.
Macrophages polarized to an M1 phenotype using IFN-γ
and LPS showed similar higher expression of these histone
markers, with the opposite true in cells polarized to an M2
phenotype or treated with GSK. We also measured nuclear
LSD1 demethylase activity in our in vitro model and showed
that phenelzine, tranylcypromine (an LSD1 inhibitor), and
macrophages polarized with IFN-γ and LPS inhibited LSD1
activity compared to control cells, whereas treatment with GSK
or M2 polarization had little effect on nuclear LSD1 activity.
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FIGURE 7 | Phenelzine affects Hippo, Wnt, and Ras signaling pathways and genes associated with ECM remodeling and metabolism. (A) Heatmap displaying the
undirected and directed global significance score statistics using the default and (B) KEGG pathway annotations. Undirected scores measure the extent of differential
expression of a geneset’s genes against control ignoring whether each gene within the set is up- or downregulated. Orange denotes genesets whose genes exhibit
extensive differential expression against control, and blue denotes genesets with less differential expression. Directed scores measure the extent to which a geneset is
up- or downregulated compared to control. Red denotes genesets that show extensive overexpression and blue denotes genesets with extensive underexpression.
(C) Venn diagram indicating genes that are differentially expressed with a false discovery rate of < 0.05 (Benjamini-Yekutieli) and top 6 pathways that those genes are
fall under. (D) Table showing the upregulated and downregulated genes that are specific to Abraxane and phenelzine.
This could potentially be due to several factors; for example,
LSD1-CoREST complex disruption by phenelzine or IFN-γ
and LPS, could destabilize the LSD1 protein in addition to
inhibiting the FAD enzymatic domain. Signaling through the
IFN-γ receptor by IFN-γ and toll-like receptors (TLR) by LPS
could also impede LSD1 demethylase activity on H3K4me2
and H3K9me2. Interestingly, we also observed that RAW264.7
cells had similar cell morphology after 7 days of treatment
to cells treated with IFN-γ and LPS (M1). This did not
occur after 24 h of treatment (data not shown), suggesting
that phenelzine might prime the macrophages to differentiate
into a similar morphology to M1 treated cells. As predicted,
the expression of nuclear phosphorylated LSD1 at serine 111
(LSD1-s111p) is lower in macrophages polarized to M1 (IFN-
γ + LPS) or treated with phenelzine. This most likely the
result of the loss of LSD1 due to the destabilization of the
LSD1-CoREST complex.
We also showed that M1 (IFN-γ + LPS)-polarized and
phenelzine-treated macrophages downregulate expression of the
transcription factor SNAIL, and previous work has shown that
SNAIL knockdown in human THP-1 macrophages and breast
cancer cells promotes M1 polarization both in vitro and in vivo
(42, 52). Therefore, inhibition of the demethylase activity of
LSD1 using phenelzine, which targets both the FAD and CoREST
domains, could play a role in M1 polarization, either directly or
indirectly through the transcription factor SNAIL. Intriguingly,
we have previously shown that this nuclear phosphorylated form
of LSD1-s111p is mediated by protein kinase-C theta (PKC-θ)
in cancer stem cells (CSCs) (22, 53). PKC-θ has been reported
to regulate various genes in T cells (54) and promotes a potent
pro-inflammatory macrophage phenotype (55). However, this
latter study may not have examined the nuclear role of PKC-
θ, so it could be possible that in the context of LSD1-s111p,
the nuclear role of PKC-θ is distinct from its cytoplasmic role
as previously shown in CSCs (22). We have also previously
shown that nuclear PKC-θ can regulate microRNAs in T cells
(56). Therefore, it would be interesting to explore the nuclear
role of PKC-θ and its ability to mediate the M1 phenotype
via LSD1.
The classically activated M1 (IFN-γ + LPS) phenotype has
been shown to have anti-tumorigenic properties. We found
that the gene signatures of RAW264.7 mouse macrophages
inhibited with phenelzine mimicked the M1-like signatures
of macrophages classically activated with IFN-γ and LPS. It
has previously been shown that the increase in demethylase
Jumonji domain containing 3 (Jmjd3) contributes to the decrease
in H3K27me2/3 and transcriptional activation of specific M2
marker genes such as Chi3l3, Retnla, and Arg1 (57). Our results
show that LSD1, another demethylase, might play a role in
regulating macrophage polarization toward an M1 phenotype.
Of therapeutic relevance, we also discovered that PD1, PD-
L1, and PD-L2 might also change when macrophages polarize,
with unpolarized cells expressing PD1, M1 cells expressing
PD-L1, and M2-polarized cells expressing PD-L2. Therefore,
these immune checkpoint proteins might be useful M1 or
M2 biomarkers.
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We hypothesized that treatment of tumor-bearing mice with
phenelzine could alter the TAMs in the TME. Using a TNBC
syngeneic mouse model, we showed that LSD1 inhibition slightly
reduced tumor volume and epigenetically reprogrammed TAMs
to a more anti-tumor phenotype. While there was no change
in the total F4/80+-expressing macrophage population, there
was a significant reduction in both inflammatory (Ly6C+) and
M2-like macrophages (CD206+). We postulated that since there
were no significant changes in the total macrophage population,
phenelzine treatment reprogrammed the macrophages already
present in the tumor toward an anti-tumor phenotype.
Interestingly, this effect was also seen with Abraxane and anti-
PD1 antibody, suggesting that phenelzine alone was able to
contribute to this reprogramming at the gene level. Our tissue
section of mice tumors showed that phenelzine and PD1 treated
mice tumors contained more macrophages expressing M1-like
markers (iNOS, CD86, and PD-L1) and lower proportions of
M2-like markers (CD206, EGR2, and PD-L2) suggesting that
phenelzine and PD1 treatment favors a M1-like phenotype in
the TME.
To further characterize the TAMs in phenelzine-treated mice,
we used the NanoString platform to show that they altered
expression of genes related to an M1 phenotype such as Il1a,
Il1b, Il6, Ccl5, Cxcl9, and Cxcl10 (58–62). There was also
increased expression of Stat1 and decreased expression of Stat3,
which are associated with M1 and M2 polarization, respectively
(58, 63, 64). Macrophages from phenelzine-treated mice also
showed a significant decrease in the NFκB1 transcription
factor compared to control. It has been shown that blocking
NFκB signaling can switch TAMs to an M1-like phenotype
(65) and that p50 overexpression in TAMs inhibits M1 anti-
tumor resistance (66). It is known that the NFκB signaling
pathway activation through TLRs induces M1 macrophage
polarization and subsequent pro-inflammatory effects through
the p65 phosphorylation and IκB (67–69), so it would be
interesting to determine whether the TLR4/NFκB signaling is
affected by phenelzine treatment. Phenelzine treatment also
significantly reduced KLF4 expression in macrophages isolated
from the TME, with KLF4 previously shown to be reduced in
M1 macrophages and robustly induced in M2 macrophages (70)
via the RORα (71) and IRF4 axes (72). We also saw a significant
increase in IRF5 expression, another M1-associated protein, on
phenelzine treatment (63, 73, 74) and Btk was similarly increased;
Btk inhibition with ibrutinib impairs M1 polarization (75,
76). Phenelzine-treated macrophages also significantly increased
TIMP3, which is a potent tumor angiogenesis and growth
inhibitor (77–79). We have previously shown using LSD1
chromatin immunoprecipitation (ChIP) sequencing that LSD1
can directly or indirectly execute genome-wide EMT via target
transcription factors (22). Therefore, it is interesting to observe
common mechanisms affecting gene regulation in CSCs and
M1 polarization.
Of note, phenelzine-treated macrophages had similar
features to the CD169+ macrophages that dominate anti-tumor
immunity via cross-presentation to cytotoxic T lymphocytes
(80–84). LSD1 inhibition also upregulated checkpoint molecules
such as CD80/86 and MHC class II genes and downregulated
negative regulators such as B7-H3. Consistent with our in
vitro polarization studies, phenelzine significantly upregulated
PD-L1. Although PD-L1 is usually an inhibitory signal, it was
upregulated when macrophages were polarized toward an M1
phenotype, and a similar trend was also seen in macrophages
isolated from Abraxane- and PD1-treated mice.
Our in silico analysis also showed that genes upregulated
by phenelzine treatment had promoters with significantly
less CpG and GC content compared to “unchanged” or
FIGURE 8 | Putative model of how LSD1 can reprogram macrophage polarization. (A) When macrophages are stimulated with LPS and IFN-γ (classical activation;
M1), disruption of CoREST destabilizes LSD1, which leads to LSD1 losing its repressive role in regulating M1-associated genes. It also increases LSD1 demethylase
activity. (B) When macrophages are stimulated with IL-4 (alternative activation; M2), CoREST is not affected, resulting in stable expression of LSD1p and LSD1
maintaining its repressive role in regulating M1-associated genes. It also decreases LSD1 demethylase activity. (C) LSD1 inhibition using phenelzine can target both
LSD1p and CoREST, mimicking a similar response to M1 polarization while (D) GSK was not able to achieve the same result because it did not disrupt the
LSD1/CoREST complex.
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downregulated genes. Conversely, downregulated gene
promoters had significantly more CpG and GC content. A
direct repressive role for LSD1 for the M1 genes is more likely to
be due to its demethylation of H3K4. High H3K4 methylation
is associated with increased DNA accessibility at promoters
and enhancer regions] and the phenelzine responsive gene
promoters are initially less accessible and more tilted toward
a lower H3K4 methylation state than the down-regulated
genes. In LPS activated cells the H3K4 methylation levels at the
phenelzine responsive gene promoters increases. We also show
that phenelzine treatments increases accessibility at both the
promoters and nearby enhancers which is mostly likely linked
to increased methylation of the surrounding histones. H3K4
methylation is dependent, not only on demethylases but also
on methylases like MLL1 and SET1 (85). MLL1 contains a CpG
binding domain, and SET1 binds an accessory protein with one
(85). It is possible that the H3K4 methylation levels of CpG
low promoters are more dependent on the levels and activity of
demethylases, while CpG high promoters are more dependent
on levels and activities of methylases.
When examining pathway changes, phenelzine inhibition
increased genes associated with the Hippo and Ras pathways but
decreased genes associated with the Wnt pathway. Upregulated
Hippo signaling sequesters β-catenin in the cytoplasm via
YAP/TAZ, negatively regulating the Wnt pathway (86). Wnt/β-
catenin signaling is activated via c-myc during monocyte to
macrophage differentiation and M2 polarization (87). Active
Wnt signaling is also implicated in macrophage-associated
angiogenesis and tumor invasion (88–90). Therefore, LSD1
can play a role in regulating genes associated with both
pathways, and LSD1 inhibition by phenelzine may be able to
reduce M2 macrophage polarization as well as macrophage-
associated angiogenesis and tumor invasion. Interestingly, we
also observed the upregulation of genes associated with Ras
signaling, a commonly dysregulated pathway in various cancer
types that regulates cell growth, survival, proliferation, and
apoptosis (91–93). How LSD1/CoREST destabilization in M1
macrophages upregulates Ras signaling would be worthy of
further study.
Overall, Abraxane treatment affected genes associated
with antigen presentation, whereas phenelzine affected genes
associated with extracellular matrix (ECM) remodeling and
metabolism. Therefore, LSD1 can modulate genes associated
with ECM remodeling and metabolism, both important
components of the TME (94–97). Since, ECM remodeling
is mainly associated with M2 macrophages, it is plausible
that phenelzine also impacts genes associated with M2
macrophages. Further studies should investigate whether
this has a positive or negative functional impact in the context
of TNBC. Macrophage function and polarization are also closely
associated with metabolic functions, with the M1 inflammatory
phenotype heavily dependent on glycolysis and M2 alternatively
activated macrophages relying on oxidative phosphorylation
[extensively reviewed in (98, 99)]. Since phenelzine treatment
affects genes associated with metabolism, there may be
the potential to epigenetically prime macrophages by
modulating LSD1.
We have previously shown that LSD1 could target gene
induction programs promoting epithelial to mesenchymal
transition (EMT) and cancer stem cells (CSC) and that inhibition
of LSD1 suppresses chemotherapy-induced EMT and cancer
associated fibroblasts (CAFs) (22). However, it is also important
to note that phenelzine could potentially affect other tumor
infiltrating subsets of cells in the TME such as effector T-
cells and myeloid-derived suppressor cells. This is beyond the
scope of this study; however, it would be a very interesting area
worth exploring.
Overall, our data proposes a model in which LSD1 poises
M1-selective gene signatures in naïve macrophages by tethering
to the epigenome of such genes, similar to in CSCs (22). LSD1
globally decorates the epigenetic landscape of M1 gene signatures
in naïve macrophages with H3K4 and H3K9 methylation marks.
Following activation of M1 signaling pathways, nuclear LSD1
activity is rapidly reduced due to the disassembly of the LSD1-
CoREST complex, leading to destabilization of the nuclear
LSD1 pool (Figure 8). This primes the epigenome of M1-
inducible genes, leading to their expression. In parallel, M2 gene
activation increases nuclear LSD1 activity and LSD1-CoREST,
in turn maintaining repression of M1 genes and skewing
induction of the M2 gene signature (Figure 8). Sequential
ChIP and co-immunoprecipitation studies will be required to
unravel the in-depth molecular signatures underlying LSD1’s
contribution to the M1/M2 phenotypes. Priming by phenelzine
alone may not be sufficient to polarize macrophages toward
a M1 phenotype, and further studies are needed to establish
which combinatorial therapies optimally enhance the phenotypes
observed in this study.
In conclusion, the LSD1 inhibitors phenelzine and GSK
are useful tools for studying the catalytic and non-catalytic
role of LSD1. These inhibitors have allowed us to dissect
the contribution of LSD1 enzymatic activity and the nuclear
LSD1-CoREST complex on M1/M2 phenotype switching.
These effects were replicated in vitro and in vivo. Inhibitors
with dual FAD and CoREST-targeting abilities could be
important for reprogramming macrophages and potentially
initiate an anti-tumor M1-like phenotype in TNBC and
other cancers.
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